Cancer news - the latest biotech news from Labiotech.eu

Home Cancer Page 97

Latest Posts

nasdaq merus biotech ipo closing immunooncology cancer breast ovarian colorectal finance

News and Trends 30 May 2016

Dutch Immuno-Oncology Biotech closes massive IPO on the NASDAQ

The Utrecht based Merus has snagged around $47.3M (€42.5M) in an IPO on the NASDAQ market for its portfolio of antibodies targeting breast and colorectal cancers. Back in April 2015, Merus announced its intention to go public on the Nasdaq, with the goal of raising at least €100M for the rest of the year, but […]

May 30, 2016 - 2 minutesmins - By Dani Bancroft

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

qiagen therawis diagnostics chemotherapy tnbc

News and Trends 26 May 2016

Qiagen partners up for Novel Diagnostic against Breast Cancer

Qiagen is partnering up with Therawis to develop a diagnostic test to predict how effective an aggressive chemotherapy will be in patients with high risk breast cancer. A giant in molecular diagnostics, Qiagen is now working in a new diagnostic test that could help guide the treatment of breast cancer. Now, Qiagen has partnered with […]

May 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

biotech immunicum cancer immunotherapy biotechnology europe

News and Trends 20 May 2016

Biotech of the Week: Immunicum, Immuno-oncology made in Sweden

We like Scandinavia so much we just don’t want to leave, therefore, we’re heading back East again! This time, Gothenburg is our destination. Being the second biggest city in Sweden and having the biggest harbor in the Northern countries (and once the hosting city for the Eurovision Song Contest in 1985) it is also where […]

May 20, 2016 - 2 minutesmins - By Joachim Eeckhout

roche fda pd l1 checkpoint inhibitor atezolizumab

News and Trends 19 May 2016

FDA approves First ever antibody to target Cancer PD-L1

Roche has received market approval for atezolizumab to treat a common type of bladder cancer. It’s the 3rd checkpoint inhibitor on the market, and the first to target PD-L1. Immuno-oncology is a hype field that promises to revolutionize cancer treatment, with a lot of active research and big deals (like the €600M deal between argenx […]

May 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

imab ganymed gastroesophegal cancer asco

News and Trends 17 May 2016

‘Ideal’ German Antibodies have promising data for Gastro Cancer

Ganymed is presenting promising results of its phase II trial in gastroesophageal cancer at the ASCO Annual meeting 2016 in Chicago, one of the leading Oncology conferences worldwide. Based in Mainz (Germany), Ganymed is a Biopharma developing immunotherapies to tackle cancer, having joined forces with BioNTech (Germany’s larget private Biotech) 2 years ago to create […]

May 17, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

abbvie bms empliciti multiple myeloma cancer immunooncology ema

News and Trends 13 May 2016

First and only antibody for Multiple Myeloma approved in EU

Bristol-Myers Squibb and AbbVie have announced that their co-development project for an antibody therapy against Multiple Myeloma has been approved in the EU after a successful Phase III trial. Empliciti (elotuzumab) has been developed for the treatment of multiple myeloma as combination therapy in patients who have received at least one prior therapy, now making it […]

May 13, 2016 - 3 minutesmins - By Dani Bancroft

oxstem regenerative medicine stem cell leukemia

News and Trends 12 May 2016

Oxford Spin-Out Raises Record €21M to Re-Program Stem Cells

OxStem’s strategy for stem cells therapy inside the body could have a big impact in regenerative medicine – and it has raised €21.4M, a record for a UK spin-out. A spin-out of Oxford University, OxStem is developing cell programming therapies that could treat a range of usually age-related conditions – dementia, heart failure, macular degeneration, […]

May 12, 2016 - 2 minutesmins - By Denise Neves Gameiro

bayer biontech veterinary mrna vaccine

News and Trends 11 May 2016

German mRNA specialist moves into Animal Health in collaboration with Bayer

BioNTech is joining its mRNA technology with Bayer’s expertise in veterinary applications in a new collaboration – to develop first-in-class vaccines for animals. Based in Mainz (Germany), BioNTech is the largest private Biotech in Europe. Along with its CAR-T and TCR programmes, BioNTech is developing mRNA therapies – a promising field in medicine. These include immunotherapies for […]

May 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

novigenix colox clinical cancer research

News and Trends 9 May 2016

Swiss Blood Test for colorectal cancer joins race of ‘Liquid Biopsies’

Novigenix has published a validation study of its molecular blood test (Colox) which can reliably detect colorectal cancer at an early stage. Is this the second-place diagnostic in the race for Colorectal cancer blood tests? Based in Lausanne (Switzerland), Novigenix is developing molecular diagnostics from a new generation of predictive gene expression profiles and tumor-derived protein markers (biomarkers). Novigenix first […]

May 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

cellectis cancer leukemia ucart19 car t cell therapy GOSH baby second biotech

News and Trends 9 May 2016

Universal CAR-T given to Second baby with aggressive Leukemia

Once again, the French biotech Cellectis has hit headlines after having treated a second infant suffering from an aggressive form of Leukemia with their UCART19 therapy. Also based at the famous Great Ormond Street Hospital (GOSH) in London, another child has been treated with the first ever Universal CAR-T cell therapy. The child in question […]

May 9, 2016 - 2 minutesmins - By Dani Bancroft

affibody stockholm biotech week header

News and Trends 6 May 2016

Biotech of the Week: Affibody and its Super antibodies from Scandinavia

From North Israel, we once again depart North towards Scandinavia to visit Sweden. On one of the several islands that make Stockholm a very particular and special European capital, our Biotech of the week Affibody has its headquarters. City: Stockholm (Sweden) – (actually just down the road from the Karolinska Institute) Founded: 1998 Employees: 22 (as of 11/2015) […]

May 6, 2016 - 2 minutesmins - By Joachim Eeckhout

ADVERTISEMENT